Thumbs up for new diabetes treatment

European medical regulators have given the thumbs up to the new AstraZeneca diabetes treatment . The drug, known as Onglyza, is a collab between the UK-based company and US group Bristol-Myers Squibb .
Onglyza (Saxagliptin) will be used to treat diabetes patients who have type 2 diabetes . It is designed to be used alone with diet and exercise, or used with metformin and other diabetes drugs to aid in blood sugar control .
The approval was based on research involving 4,000 diabetes patients and reportedly proved that the drug can significantly reduce blood sugar levels when added to regular diabetes treatments . The drug is one of the first DPP-4 inhibitors to be approved, and is also less likely to cause weight gain.